Singlet oxygen

Theralase Expands Intellectual Property Portfolio

Retrieved on: 
Tuesday, June 28, 2022

Theralase has recently been granted a Brazilian patent for, Metal-Based Thiopene Photodynamic Compounds and their Use (Patent).

Key Points: 
  • Theralase has recently been granted a Brazilian patent for, Metal-Based Thiopene Photodynamic Compounds and their Use (Patent).
  • The patent advances Theralases intellectual property portfolio internationally strengthening the patent portfolio around the Anti-Cancer Technology (ACT) platform.
  • This patent further strengthens the extensive portfolio of patents already held by Theralase.
  • Arkady Mandel, M.D., Ph.D., D.Sc., Interim Chief Executive Officer (CEO) and Chief Scientific Officer (CSO), Theralase stated that, This patent is strategic to opening up new international opportunities for Theralase by expanding its IP portfolio of medical laser and oncology focused technologies internationally.

USMI and JCRI Research Teams Develop Treatment System for COVID and other Respiratory Infections and Diseases

Retrieved on: 
Wednesday, October 6, 2021

17/284,762) entitled SYSTEM FOR TREATMENT OF RESPIRATORY INFECTIONS AND CANCERS OF THE RESPIRATORY SYSTEM USING COLD ATMOSPHERIC PLASMA.

Key Points: 
  • 17/284,762) entitled SYSTEM FOR TREATMENT OF RESPIRATORY INFECTIONS AND CANCERS OF THE RESPIRATORY SYSTEM USING COLD ATMOSPHERIC PLASMA.
  • Jerome Canady, MD (CEO of USMI) stated, This is a very important addition to the companys patent portfolio.
  • JCRI-ABTS is also conducting research using the HERO system to deliver CAPs to treat cancer and other diseases to the abdomen and other body cavities via cannulas, laparoscopes, and endoscopes.
  • JCRI-ABTS is using Canady Helios Cold Plasma to research and develop new methods to selectively treat and eradicate cancer.